Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.35 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5698087 | 0.88 | NOD1 (0.43) | NOD1SLC6A5GNPATSLC15A2MME | |
| SCHEMBL4008880 | 0.88 | NOD1 (0.43) | NOD1SLC6A5GNPATSLC15A2MME | |
| SCHEMBL5698138 | 0.85 | NOD1 (0.48) | NOD1SLC6A5GNPAT | |
| SCHEMBL4009812 | 0.85 | NOD1 (0.48) | NOD1SLC6A5GNPAT | |
| SCHEMBL19586694 | 0.84 | FOLH1 (0.42) | NOD1SLC6A5GNPATSLC15A2FOLH1 | |
| SCHEMBL19586695 | 0.84 | FOLH1 (0.42) | NOD1SLC6A5GNPATSLC15A2FOLH1 | |
| SCHEMBL7175773 | 0.82 | NOD1 (0.49) | NOD1SLC6A5GNPATSLC15A2FOLH1 | |
| SCHEMBL7175771 | 0.82 | NOD1 (0.49) | NOD1SLC6A5GNPATSLC15A2FOLH1 | |
| SCHEMBL1133639 | 0.81 | POLB (0.40) | NOD1SLC6A5GNPATFOLH1NAALAD2 | |
| SCHEMBL8468722 | 0.81 | POLB (0.40) | NOD1SLC6A5GNPATFOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | claimed |
| EP-1670750-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030703-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | claimed |
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1670750-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030703-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | NOD1 3810/4885SLC6A5 826/4885GNPAT 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.